Table 1.

Demographic and clinicopathologic characteristics in 507 patients who underwent resection of CLM

Characteristic	Value
Patient factors
Age, median (IQR), yr	55 (46–62)
Sex, male : female, n	286 : 221
ASA score ≥ 3, n (%)	442 (87.2%)
Primary lesion factors
Location, colon : rectum, n	358 : 149
T category ≥ 3, n (%)*	436 (87.4)
Lymph node metastasis, n (%)*	354 (71.8)
Liver metastases clinical factors
Prehepatectomy CEA level, median (IQR), ng/mL	4.0 (2.2–12.5)
Synchronous metastasis, n (%)	382 (75.3%)
Extrahepatic metastasis, n (%)	83 (16.4%)
Prehepatectomy chemotherapy, n (%)	455 (89.7%)
> 6 cycles, n (%)	142 (28.0%)
Oxaliplatin-containing regimen	374 (73.8%)†
Irinotecan-containing regimen	107 (21.1%)‡
With anti-VEGF agent, n (%)	356 (70.2%)§
With anti-EGFR agent, n (%)	39 (7.7%)¶
Liver metastases histopathologic factors
Tumor number, median (IQR)	2 (1–4)
Maximum diameter, median (IQR), cm	2.5 (1.5–4.0)
R1 surgical margin, n (%)	104 (20.5%)

Abbreviations: IQR, interquartile range; ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen; VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor.

^*Data not available for T category in 8 patients and lymph node metastasis in 14 patients.

^†Patients with RAS mutation vs. patients with RAS wild-type.191 (74.3%) vs. 183 (73.2%), P = 0.840.

^‡Patients with RAS mutation vs. patients with RAS wild-type.49 (19.1%) vs. 58 (23.2%), P = 0.277.

^§Patients with RAS mutation vs. patients with RAS wild-type.183 (71.2%) vs. 173 (69.2%), P = 0.629.

^¶Patients with RAS mutation vs. patients with RAS wild-type.4 (1.6%) vs. 35 (14.0%), P < 0.001.